Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01911767 · ClinicalTrials.gov registry record
Biogen Multiple Sclerosis Pregnancy Exposure Registry
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 408
- Enrollment target
NCT01911767 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 408 participants.
The verdict
NCT01911767 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 408 participants
- Enrollment target
Study Summary
The primary objective of the study is to prospectively evaluate pregnancy outcomes in women with multiple sclerosis who were exposed to a Registry-specified Biogen Multiple Sclerosis product during the eligibility window for that product. The Registry-specified Biogen MS products being studied are dimethyl fumarate, and Pegylated human interferon beta-1a. The secondary objective of the study is to prospectively evaluate pregnancy outcomes in women with MS who were unexposed to disease-modifying therapies (DMTs).
Interventions
- DRUG Dimethyl fumarate
- DRUG Peginterferon beta-1a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2013-10-30 |
| Est. Completion | 2022-02-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01911767
The ClinicalTrials.gov registry entry for NCT01911767 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 408 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dimethyl fumarate is the first listed.
NCT01911767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01911767 about?
NCT01911767 is a clinical study titled "Biogen Multiple Sclerosis Pregnancy Exposure Registry". The primary objective of the study is to prospectively evaluate pregnancy outcomes in women with multiple sclerosis who were exposed to a Registry-specified Biogen Multiple Sclerosis product during the eligibility window for that product. The Registry-specified Biogen MS products being studied are d...
What is the current status of trial NCT01911767?
This trial is currently completed. The enrollment target is 408 participants. The study started on 2013-10-30. Estimated completion is 2022-02-10.
What interventions are being tested in trial NCT01911767?
The interventions under investigation include: Dimethyl fumarate (DRUG), Peginterferon beta-1a (DRUG).
Who is sponsoring clinical trial NCT01911767?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.